Skip to main content
. 2022 Mar 31;10(3):e003939. doi: 10.1136/jitc-2021-003939

Figure 2.

Figure 2

rBCG-S.FimH exhibited enhanced antitumor effect than wild-type BCG in vivo. (A) Schematic representation of the experimental design. C57BL/6 mice were intravesically inoculated with 1×106 MB49-luc cells, and treated with PBS, 2.5 mg/kg FimH, 2.5×105 CFU/mL BCG, 2.5×105 CFU/mL BCG with 2.5 mg/kg FimH or 2.5×105 CFU/mL rBCG-S.FimH two times a week for 4 weeks. Bladders were harvested 28 days after treatment. (B) IVIS images of mice from different treatment groups at day 7. (C) Image of the bladders at the end of the experiment. (D) The growth curve of tumors as monitored by IVIS from day 7 to day 21 (n=8 mice, one-way analysis of variance (ANOVA), mean ± SD). (E) Weight of the bladders at the end of the experiment (n=8 mice, one-way ANOVA, mean ± SEM). (F) Representative H&E staining of the bladders at the end of the experiment showing reduced tumor burden in the rBCG-S.FimH group. scale bar: 100 µm. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001. PBS, phosphate buffered saline. IVIS, in vivo imaging system.